HRP20170687T1 - Agensi koji iscrpljuju b-stanice, kao anti-cd20 protutijela ili njihovi fragmenti za liječenje sindroma kroničnog umora - Google Patents
Agensi koji iscrpljuju b-stanice, kao anti-cd20 protutijela ili njihovi fragmenti za liječenje sindroma kroničnog umora Download PDFInfo
- Publication number
- HRP20170687T1 HRP20170687T1 HRP20170687TT HRP20170687T HRP20170687T1 HR P20170687 T1 HRP20170687 T1 HR P20170687T1 HR P20170687T T HRP20170687T T HR P20170687TT HR P20170687 T HRP20170687 T HR P20170687T HR P20170687 T1 HRP20170687 T1 HR P20170687T1
- Authority
- HR
- Croatia
- Prior art keywords
- cell depleting
- antibody
- use according
- depleting agent
- cell
- Prior art date
Links
- 210000003719 b-lymphocyte Anatomy 0.000 title claims 16
- 230000000779 depleting effect Effects 0.000 title claims 16
- 239000003795 chemical substances by application Substances 0.000 title claims 11
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 title claims 4
- 239000012634 fragment Substances 0.000 title claims 4
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 title claims 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 8
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 5
- 206010057244 Post viral fatigue syndrome Diseases 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960003347 obinutuzumab Drugs 0.000 claims 1
- 229950005751 ocrelizumab Drugs 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229950000815 veltuzumab Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (9)
1. Agens za iscrpljivanje B-stanica za uporabu u liječenju sindroma kroničnog umora i mijalgičkog encefalomijelitisa gdje je agens koji iscrpljuje B-stanice deplecijsko anti CD20 protutijelo za B-stanice ili njegov CD20-vezujući fragment protutijela.
2. Deplecijsko anti CD20 protutijelo za B-stanice ili njegov CD20-vezujući fragment za uporabu u skladu s patentnim zahtjevom 1, koje je monoklonsko protutijelo ili njegov CD20-vezujući fragment protutijela.
3. Agens za iscrpljivanje B-stanica za uporabu u skladu s patentnim zahtjevom 1, koji je humanizirano anti CD20 protutijelo ili njegov CD20-vezujući fragment protutijela.
4. Agens za iscrpljivanje B-stanica za uporabu u skladu s patentnim zahtjevom 1, koji je antigen vezujući fragment odabran iz grupe koja se sastoji od F(ab’)2, F(ab’), Fab, Fv i sFv.
5. Agens za iscrpljivanje B-stanica za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva koji je odabran između humaniziranih protutijela rituksimaba, ofatumumaba, okrelizumaba, GA101 ili veltuzumaba.
6. Agens za iscrpljivanje B-stanica za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, pri čemu je količina za B-stanice deplecijskog anti CD20 protutijela u rasponu od 10 mg do 5000 mg po doziranju.
7. Agens za iscrpljivanje B-stanica za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 6, pri čemu je deplecijsko anti CD20 protutijelo za B-stanice ili njegov CD20-vezujući fragment protutijela za davanje subjektu u pojedinačnoj terapijski učinkovitoj dozi navedenog protutijela od 50 do 2000 mg/m2 ili višestrukim terapijski učinkovitim dozama navedenog anti CD20 protutijela ili anti CD20 vezujućeg fragmenta protutijela od 50 do 2000 mg/m2.
8. Agens za iscrpljivanje B-stanica za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 7 primjenom jedne ili dviju infuzija navedenog deplecijskog agensa za B-stanice dva puta unutar dva tjedna.
9. Agens za iscrpljivanje B-stanica za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva karakteriziran primjenom kombinacije deplecijskog anti CD20 protutijela za B-stanice ili njegovog CD20-vezujućeg fragmenta protutijela istovremeno, zasebno ili u slijedu s metotreksatom subjektu koji pati od sindroma kroničnog umora ili mijalgičkog encefalomijelitisa.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1855108P | 2008-01-02 | 2008-01-02 | |
| EP08000006A EP2077281A1 (en) | 2008-01-02 | 2008-01-02 | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| EP09700128.3A EP2235060B1 (en) | 2008-01-02 | 2009-01-02 | B-cell depleting agents, like anti-cd20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| PCT/EP2009/000003 WO2009083602A1 (en) | 2008-01-02 | 2009-01-02 | B-cell depleting agents, like anti-cd20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170687T1 true HRP20170687T1 (hr) | 2017-09-08 |
Family
ID=39402622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170687TT HRP20170687T1 (hr) | 2008-01-02 | 2017-05-08 | Agensi koji iscrpljuju b-stanice, kao anti-cd20 protutijela ili njihovi fragmenti za liječenje sindroma kroničnog umora |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP2077281A1 (hr) |
| JP (1) | JP5722044B2 (hr) |
| KR (1) | KR101652530B1 (hr) |
| CN (1) | CN101910201B (hr) |
| AU (1) | AU2009203117B2 (hr) |
| BR (1) | BRPI0906172A2 (hr) |
| CA (1) | CA2706899C (hr) |
| CY (1) | CY1118918T1 (hr) |
| DK (1) | DK2235060T3 (hr) |
| ES (1) | ES2625728T3 (hr) |
| HR (1) | HRP20170687T1 (hr) |
| HU (1) | HUE034127T2 (hr) |
| IL (1) | IL206767A (hr) |
| LT (1) | LT2235060T (hr) |
| PL (1) | PL2235060T3 (hr) |
| PT (1) | PT2235060T (hr) |
| RU (1) | RU2519229C2 (hr) |
| SI (1) | SI2235060T1 (hr) |
| WO (1) | WO2009083602A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6012473B2 (ja) * | 2010-01-11 | 2016-10-25 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー |
| KR102316283B1 (ko) * | 2011-05-16 | 2021-10-21 | 젠자임 코포레이션 | 메토트렉세이트를 이용한 면역 관용의 유도 |
| EP2805730A1 (en) * | 2013-05-21 | 2014-11-26 | Bergen Teknologioverforing AS | Nitric oxide donor for the treatment of chronic fatigue syndrome |
| EP3062780A1 (en) * | 2013-11-01 | 2016-09-07 | Bergen Teknologioverføring AS | Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome |
| WO2016102530A1 (en) * | 2014-12-22 | 2016-06-30 | Bergen Teknologioverføring As | Cyclic phosphoric acid derivative for the treatment of chronic fatigue syndrome |
| US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
| US20210169930A1 (en) * | 2018-04-17 | 2021-06-10 | National Cancer Center | Anticancer t cell therapy product-assisting composition comprising depleting anti-cd4 monoclonal antibody and use thereof |
| EP3569617A1 (en) * | 2018-05-18 | 2019-11-20 | Trion Research GmbH | Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases |
| AU2020339737A1 (en) | 2019-08-30 | 2022-03-17 | Vestlandets Innovasjonsselskap As | Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1989008114A1 (en) | 1988-02-25 | 1989-09-08 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US4861579A (en) | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| WO1993016177A1 (en) | 1992-02-11 | 1993-08-19 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| US5417972A (en) | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6387638B1 (en) | 1997-02-10 | 2002-05-14 | Genentech, Inc. | Heregulin variants |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| DK0999853T3 (da) | 1997-06-13 | 2003-04-22 | Genentech Inc | Stabiliseret antostofformulering |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| AU757627B2 (en) | 1997-06-24 | 2003-02-27 | Genentech Inc. | Methods and compositions for galactosylated glycoproteins |
| WO1999002567A2 (en) | 1997-07-08 | 1999-01-21 | Board Of Regents, The University Of Texas System | Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
| ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ATE414536T1 (de) | 1998-08-11 | 2008-12-15 | Biogen Idec Inc | Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20- antikörpern |
| US6224866B1 (en) | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
| JP2002529429A (ja) | 1998-11-09 | 2002-09-10 | アイデック・ファーマシューティカルズ・コーポレイション | Ｂｍｔまたはｐｂｓｃ移植を受ける患者のキメラ化抗ｃｄ２０抗体による治療。 |
| EP1949910A1 (en) | 1998-11-09 | 2008-07-30 | Biogen Idec, Inc. | Treatment of chronic lymphocytic leukemia (CLL) using chimeric anti-CD20 antibody. |
| KR20060067983A (ko) | 1999-01-15 | 2006-06-20 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
| US6383276B1 (en) | 1999-03-12 | 2002-05-07 | Fuji Photo Film Co., Ltd. | Azomethine compound and oily magenta ink |
| MXPA01011279A (es) * | 1999-05-07 | 2002-07-02 | Genentech Inc | Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b. |
| EP1194167B1 (en) | 1999-06-09 | 2009-08-19 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| ITMI991299A1 (it) | 1999-06-11 | 2000-12-11 | Consiglio Nazionale Ricerche | Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite |
| DE19930748C2 (de) | 1999-07-02 | 2001-05-17 | Infineon Technologies Ag | Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip |
| CA2379274A1 (en) | 1999-07-12 | 2001-01-18 | Genentech, Inc. | Blocking immune response to a foreign antigen using an antagonist which binds to cd20 |
| JP2003513012A (ja) | 1999-08-11 | 2003-04-08 | アイデック ファーマスーティカルズ コーポレイション | 抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療 |
| US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
| US6451284B1 (en) | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
| AU6929100A (en) | 1999-08-23 | 2001-03-19 | Biocrystal Limited | Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| WO2001034194A1 (en) | 1999-11-08 | 2001-05-17 | Idec Pharmaceuticals Corporation | Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
| AU2001247737A1 (en) | 2000-03-24 | 2001-10-08 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2 |
| US20030185796A1 (en) | 2000-03-24 | 2003-10-02 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma |
| CN1981868A (zh) | 2000-03-31 | 2007-06-20 | 拜奥根Idec公司 | 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用 |
| EP1272647B1 (en) | 2000-04-11 | 2014-11-12 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| WO2001080884A1 (en) | 2000-04-25 | 2001-11-01 | Idec Pharmaceuticals Corporation | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
| EP2052742A1 (en) | 2000-06-20 | 2009-04-29 | Biogen Idec Inc. | Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination |
| WO2001097843A2 (en) | 2000-06-22 | 2001-12-27 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
| JP2004502742A (ja) | 2000-07-12 | 2004-01-29 | アイデック ファーマスーティカルズ コーポレイション | Ｂ細胞を消滅させる抗体及び免疫調節抗体を併用するｂ細胞悪性疾患の治療関連出願 |
| WO2002022212A2 (en) | 2000-09-18 | 2002-03-21 | Idec Pharmaceuticals Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| WO2002034790A1 (en) | 2000-10-20 | 2002-05-02 | Idec Pharmaceuticals Corporation | Variant igg3 rituxan r and therapeutic use thereof |
| KR100923514B1 (ko) | 2000-12-28 | 2009-10-27 | 알투스 파마슈티컬스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
| NZ545176A (en) | 2001-01-29 | 2008-05-30 | Biogen Idec Inc | Modified antibodies reactive with CD20 and methods of use |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| US20030103971A1 (en) | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
| US20020197256A1 (en) | 2001-04-02 | 2002-12-26 | Genentech, Inc. | Combination therapy |
| EP1383800A4 (en) | 2001-04-02 | 2004-09-22 | Idec Pharma Corp | RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII |
| WO2003061694A1 (en) | 2001-05-10 | 2003-07-31 | Seattle Genetics, Inc. | Immunosuppression of the humoral immune response by anti-cd20 antibodies |
| JP2005515161A (ja) | 2001-06-14 | 2005-05-26 | インターミューン インコーポレイテッド | γ−インターフェロンおよびＢ細胞特異的抗体の併用療法 |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| EP2131198B1 (en) | 2001-09-20 | 2013-03-27 | Board of Regents, The University of Texas System | Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays |
| AU2002337935B2 (en) | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
| WO2003049694A2 (en) | 2001-12-07 | 2003-06-19 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma |
| CA2476166C (en) | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| US20030180292A1 (en) | 2002-03-14 | 2003-09-25 | Idec Pharmaceuticals | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
| US20030219818A1 (en) | 2002-05-10 | 2003-11-27 | Bohen Sean P. | Methods and compositions for determining neoplastic disease responsiveness to antibody therapy |
| US20050180972A1 (en) | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| MXPA05004022A (es) | 2002-10-17 | 2005-10-05 | Genmab As | Anticuerpos monoclonales humanos contra cd20. |
| MXPA06005104A (es) * | 2003-11-05 | 2007-01-25 | Palingen Inc | Citotoxicidad de celulas b aumentada en anticuerpos de enlace a cdim. |
| AU2005244751A1 (en) * | 2004-04-16 | 2005-12-01 | Genentech, Inc. | Method for augmenting B cell depletion |
| CN101267836A (zh) * | 2005-07-25 | 2008-09-17 | 特鲁比昂药品公司 | 单剂量cd20特异性结合分子的用途 |
| DE102005035611C5 (de) | 2005-07-29 | 2014-05-15 | Diehl Aerospace Gmbh | Busarchitektur sowie Verfahren zum Datenaustausch |
| CN101351478A (zh) * | 2005-11-01 | 2009-01-21 | 诺华有限公司 | 抗cd40抗体的应用 |
| CA2629306A1 (en) * | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
-
2008
- 2008-01-02 EP EP08000006A patent/EP2077281A1/en not_active Withdrawn
-
2009
- 2009-01-02 HU HUE09700128A patent/HUE034127T2/en unknown
- 2009-01-02 KR KR1020107014813A patent/KR101652530B1/ko active IP Right Grant
- 2009-01-02 WO PCT/EP2009/000003 patent/WO2009083602A1/en active Application Filing
- 2009-01-02 AU AU2009203117A patent/AU2009203117B2/en not_active Ceased
- 2009-01-02 PL PL09700128T patent/PL2235060T3/pl unknown
- 2009-01-02 CN CN200980101646.6A patent/CN101910201B/zh not_active Expired - Fee Related
- 2009-01-02 LT LTEP09700128.3T patent/LT2235060T/lt unknown
- 2009-01-02 CA CA2706899A patent/CA2706899C/en not_active Expired - Fee Related
- 2009-01-02 JP JP2010541057A patent/JP5722044B2/ja not_active Expired - Fee Related
- 2009-01-02 DK DK09700128.3T patent/DK2235060T3/en active
- 2009-01-02 EP EP09700128.3A patent/EP2235060B1/en active Active
- 2009-01-02 SI SI200931662T patent/SI2235060T1/sl unknown
- 2009-01-02 ES ES09700128.3T patent/ES2625728T3/es active Active
- 2009-01-02 BR BRPI0906172-0A patent/BRPI0906172A2/pt not_active Application Discontinuation
- 2009-01-02 PT PT97001283T patent/PT2235060T/pt unknown
- 2009-01-02 RU RU2010132178/15A patent/RU2519229C2/ru active
-
2010
- 2010-07-01 IL IL206767A patent/IL206767A/en active IP Right Grant
-
2017
- 2017-05-08 HR HRP20170687TT patent/HRP20170687T1/hr unknown
- 2017-05-22 CY CY20171100535T patent/CY1118918T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2077281A1 (en) | 2009-07-08 |
| JP2011508754A (ja) | 2011-03-17 |
| WO2009083602A1 (en) | 2009-07-09 |
| IL206767A0 (en) | 2010-12-30 |
| IL206767A (en) | 2015-03-31 |
| BRPI0906172A2 (pt) | 2015-06-30 |
| CA2706899A1 (en) | 2009-07-09 |
| ES2625728T3 (es) | 2017-07-20 |
| PT2235060T (pt) | 2017-05-31 |
| CY1118918T1 (el) | 2018-01-10 |
| KR20100116172A (ko) | 2010-10-29 |
| CN101910201B (zh) | 2015-01-21 |
| CN101910201A (zh) | 2010-12-08 |
| AU2009203117B2 (en) | 2014-10-23 |
| CA2706899C (en) | 2017-02-28 |
| LT2235060T (lt) | 2017-07-25 |
| AU2009203117A1 (en) | 2009-07-09 |
| EP2235060A1 (en) | 2010-10-06 |
| JP5722044B2 (ja) | 2015-05-20 |
| KR101652530B1 (ko) | 2016-08-30 |
| SI2235060T1 (sl) | 2017-09-29 |
| PL2235060T3 (pl) | 2017-10-31 |
| RU2519229C2 (ru) | 2014-06-10 |
| HUE034127T2 (en) | 2018-01-29 |
| DK2235060T3 (en) | 2017-06-06 |
| EP2235060B1 (en) | 2017-03-29 |
| RU2010132178A (ru) | 2012-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170687T1 (hr) | Agensi koji iscrpljuju b-stanice, kao anti-cd20 protutijela ili njihovi fragmenti za liječenje sindroma kroničnog umora | |
| AU2012280267B2 (en) | Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof | |
| JP6177133B2 (ja) | Ｃｄ３８を特異的に認識する抗体とボルテゾミブを含有する抗腫瘍性の組合せ | |
| JP2019513751A5 (hr) | ||
| Smith et al. | Painful rheumatoid arthritis | |
| JP2019518742A5 (hr) | ||
| JP2014533279A5 (hr) | ||
| JP2019506403A5 (hr) | ||
| NZ599278A (en) | Methods of reducing eosinophil levels | |
| JP2006522830A5 (hr) | ||
| JP2008540447A5 (hr) | ||
| JP2013512254A5 (hr) | ||
| JP2012046518A5 (hr) | ||
| JP2011504092A5 (hr) | ||
| JP2019517485A5 (hr) | ||
| ES2909722T3 (es) | Terapia de combinación con un anticuerpo anti-CD19 y una mostaza nitrogenada | |
| RU2756405C2 (ru) | Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения | |
| US20200231666A1 (en) | Treatment paradigm | |
| JP2017529324A5 (hr) | ||
| RU2013127115A (ru) | Комбинированная терапия при в-клеточных лимфомах | |
| JP2013543869A5 (hr) | ||
| MX2021013248A (es) | Regimenes de dosificacion para anticuerpos anti-vrs y composiciones que los incluyen. | |
| WO2016003789A1 (en) | Combination therapy | |
| CN111655725A (zh) | 用于治疗癌症的组合产品 | |
| Wood et al. | Rituximab |